Q&A: Page 8
Exclusive interviews with industry leaders
-
Getty Images
Biotech spotlight: Twist Bioscience aims to remove limits on drug discovery with DNA synthesis platform
As ‘the Amazon of DNA,’ Twist CSO, Aaron Sato, discusses the company’s breakthrough approach to DNA production and its expansion into drug development.
Kim Ribbink • June 30, 2022 -
Permission granted by University of Pennsylvania
The scientist's struggle: Lessons from the journey of mRNA pioneers Katalin Karikó and Drew Weissman
The two Penn Medicine researchers whose work brought the mRNA vaccines into COVID-19 fruition want to see the pharma world embrace early science.
Michael Gibney • June 29, 2022 -
Permission granted by Dan Vahdat.
'Nobel Prize of pharma' helps put Huma's digital health platform on the global map
The company’s CEO explains how its Prix Galien award-winning app bridges patient care, treatment support and clinical research.
Kim Ribbink • June 23, 2022 -
Getty Images
Biotech spotlight: Karuna Therapeutics’ mission to rejuvenate the field of neuroscience
An effective treatment for psychiatric disorders such as schizophrenia might require a holistic approach to avoid serious side effects, says CEO Steve Paul.
Kim Ribbink • June 16, 2022 -
Getty Images
Why biomanufacturing is the next innovation frontier for genomic therapies
While cell and gene therapy research has accelerated quickly, manufacturing in the space hasn’t quite kept up, Danaher’s Chief Science Officer JC Gutiérrez-Ramos says.
Meagan Parrish • June 13, 2022 -
Permission granted by Editas/Gilmore O'Neill
First 90 Days: Editas Medicine’s Gilmore O’Neill
The first-time CEO is flexing new muscles as he steers the gene editing company through clinical trials and beyond.
Michael Gibney • June 13, 2022 -
Getty Images
A combo of precision meds and diagnostics could disrupt mental healthcare
HMNC Brain Health, a clinical-stage company, is leveraging cutting-edge tech to offer a new approach to mental health challenges.
Kelly Bilodeau • June 8, 2022 -
Permission granted by David Jimenez.
First 90 Days: Janssen Immunology’s David Jimenez
The long-time company man discusses the mega-drugmaker’s plans for growth and why, if you meet with him, you should plan on sipping coffee.
Taren Grom • June 6, 2022 -
Permission granted by Sosei Heptares/Chris Cargill
First 90 Days: Sosei Heptares’ Chris Cargill
The company’s new CEO is looking to drive growth through collaboration and transparency.
Kim Ribbink • May 31, 2022 -
Permission granted by Michelle Keefe.
First 90 Days: Syneos Health’s Michelle Keefe
The newly minted CEO is leaning on her 30 years of experience leading high-performance teams to make her mark at Syneos.
Taren Grom • May 23, 2022 -
Getty Images
The UK-based company that's striving to overcome the limitations of T cell receptor innovation
Etcembly’s CEO, Michelle Teng, shares why a platform approach to T cell receptors can advance and democratize innovation.
Kim Ribbink • May 23, 2022 -
Getty Images
Ironwood Pharmaceuticals is charting a course to become a giant in GI
Ironwood’s CEO, Tom McCourt, discusses the company’s strategy for leveling up in the GI market.
Karissa Waddick • May 19, 2022 -
Spencer Platt via Getty Images
BriOri BioTech sets the stage for the comeback of Vioxx
With a topical pain-relieving ointment in development, the emerging biotech is aiming to give the tarnished NSAID a new life.
Kelly Bilodeau • May 17, 2022 -
Getty Images
Biotech Spotlight: Graphite Bio seeks sickle cell cure with a next-gen approach
Using gene editing, CEO Josh Lehrer says the company is poised to ‘offer a cure’ to a long list of diseases.
Michael Gibney • May 17, 2022 -
Getty Images
Biotech Spotlight: Everest Medicines takes aim at unmet needs in Asia
With a multi-pronged business strategy, Everest Medicines is positioning itself as a ‘rising force’ in Asian biotech.
Taren Grom • May 9, 2022 -
Getty Images
One company's failed drug is this company's 'jewel'
Dr. Thomas Bock, CEO of Notable, is helping the company develop a ‘new class’ of predictive precision medicines in oncology.
Meagan Parrish • May 2, 2022 -
Permission granted by Alan Millar.
How an open platform can shake up the drug development process
TetraScience’s Alan Millar shares why pharma is rethinking data integration in the race to be faster, better and more effective.
Kim Ribbink • April 28, 2022 -
Getty Images
Real-world data is making drug development more true to life
How RWD is moving from the background to the spotlight in pharma’s development process.
Kelly Bilodeau • April 26, 2022 -
Getty Images
How OliX Pharmaceuticals is riding the RNAi wave
While the company may look like “the new kid on the block,” CEO Dong-ki Lee says the Korean biotech is ready for the global stage.
Karissa Waddick and Taren Grom • April 25, 2022 -
Getty Images
The cannabis vanguard: A rare disease company looks to pioneer in the space
Zynerba’s CEO shares his views on advances in cannabidiol treatments for neuropsychiatric illnesses and the regulatory environment for CBD-based drugs.
Jared Whitlock • April 21, 2022 -
Getty Images
A psychedelic pill for alcoholism? The CEO of Clearmind Medicine says 'Yes.'
Known to provide a “euphoric” experience, MEAI started out as a recreational drug used as an alcohol substitute. Now, Adi Zuloff-Shani says it may even treat alcohol addiction.
Alexandra Pecci • April 21, 2022 -
Getty Images
How pharma can up its social media game
Health Union’s VP of community development, Sara Hayes, discusses how pharma marketers can better reach online patient communities.
Karissa Waddick • April 18, 2022 -
Getty Images
Biotech goes Hollywood
A few years ago, the biotech venture world in LA was almost ‘nonexistent’ — now Joseph Panetta, CEO of Biocom California, says the region is undergoing a major change.
Taren Grom • April 13, 2022 -
Stock via Getty Images
Down but not out: How AVEO's CEO steered the company past an FDA rejection
Michael Bailey explains why focusing on the patient helped AVEO clear regulatory hurdles to bring a new cancer drug across the finish line.
Kim Ribbink • April 5, 2022 -
Real Chemistry/PharmaVoice
Lessons from improv: Shankar Narayanan’s ‘yes, and’ approach to healthcare leadership
Real Chemistry's CEO is bringing a unique set of skills to the role as he sets off on a company-wide listening tour.
Taren Grom • April 4, 2022
Previous
